Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026GlobeNewsWire • 03/02/26
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/26
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)GlobeNewsWire • 01/05/26
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal CarcinomaGlobeNewsWire • 12/08/25
Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/10/25
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic AntibodyGlobeNewsWire • 11/07/25
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/25
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs OfficerGlobeNewsWire • 11/06/25
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewsWire • 10/30/25
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/03/25
Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day TranscriptSeeking Alpha • 10/01/25
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25